Abstract:Introduction: Azole resistance has been increasingly reported and become an issue for clinical managements of invasive mycoses. New strategy with combination therapy arises as a valuable and promising alternative option. The aim of the present study is to investigate the in vitro combinational effect of proton pump inhibitors (PPIs) and azoles against pathogenic fungi. Methods: In vitro interactions of PPIs including omeprazole (OME), lansoprazole (LAN), pantoprazole (PAN), and rabeprazole (RAB), and commonly used azoles including itraconazole (ITC), posaconazole (POS), voriconazole (VRC) and FLC, were investigated via broth microdilution chequerboard procedure adapted from the CLSI M27-A3 and M38-A2. A total of 67 clinically isolated strains, namely 27 strains of Aspergillus spp., 16 strains of Candida spp., and 24 strains of dematiaceous fungi, were studied. C. parapsilosis (ATCC 22019) and A. flavus (ATCC 204304) was included to ensure quality control. Results: PPIs individually did not exert any significant antifungal activity. The combination of OME with ITC, POS, or VRC showed synergism against 77.6%, 86.6%, and 4% strains of tested pathogenic fungi, respectively, while synergism of OME/FLC was observed in 50% strains of Candida spp. Synergism between PAN and ITC, POS, or VRC was observed against 47.8%, 77.6% and 1.5% strains of tested fungi, respectively, while synergism of PNA/FLC was observed in 50% strains of Candida spp. Synergism of LAN with ITC, POS, or VRC was observed against 86.6%, 86.6%, and 3% of tested strains, respectively, while synergism of LAN/FLC was observed in 31.3% strains of Candida spp. Synergy of the combination of RAB with ITC, POS, or VRC was observed against 25.4%, 64.2%, and 4.5% of tested strains, respectively., synergism of RAB/FLC was observed in 12.5% of Candida spp.. Among PPIs, synergism was least observed between RAB and triazoles, while among triazoles, synergism was least observed between VRC and PPIs. Among species, synergy was much more frequently observed in Aspergillus spp. and dematiaceous fungi as compared to Candida spp. Antagonism between PPIs with ITC or VRC was occasionally observed in Aspergillus spp. and dematiaceous fungi. It is notable that PPIs combined with azoles showed synergy against azole resistant A. fumigatus , and resulted in category change of susceptibility of ITC and POS against Candida spp. Discussion: The results suggested that PPIs combined with azoles has the potential to enhance the susceptibilities of azoles against multiple pathogenic fungi and could be a promising strategy to overcome azole resistance issues. However, further investigations are warranted to study the combinational efficacy in more isolates and more species, to investigate the underlying mechanism of interaction and to evaluate the potential for concomitant use of these agents in human.

In Vitro Interaction of Itraconazole with Amphotericin B, Caspofungin, and Terbinafine Against Clinical Isolates of Trichosporon asahii

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

In Vitro Combined Activity of Amphotericin B, Caspofungin and Voriconazole Against Clinical Isolates of Trichosporon Asahii

Terbinafine versus itraconazole for treatment of dermatophyte onychomycosis: a meta-analysis

In vitro interactions of itraconazole with caspofungin or terbinafine against Sporothrix globosa

In Vitro Interaction of Terbinafine with Itraconazole and Amphotericin B Against Fungi Causing Chromoblastomycosis in China.

In Vitro Activity of Isavuconazole and Amphotericin B in Association against Mucorales

In vitro susceptibility testing of the combination of terbinafine and itraconazole against dematiaceous fungi

In vitro activities of six antifungal agents and their combinations against Chaetomium spp.

Combination of itraconazole and terbinafine in treating sporotrichosis and their in vitro antifungal activities against Sporothrix schenckii

Antifungal activity of combination of caspofungin and voriconazole, itraconazole or amphotericin B against clinical strains of Scedosporium apiospermum in vitro

Synergistic effects of terbinafine and itraconazole on clinical isolates of Fonsecaea monophora.

Activities of Terbinafine in Combination with Itraconazole and Fluconazole Against Isolates of Candida albicans In Vitro

Increased Triazole-Resistance and Cyp51a Mutations in Aspergillus Fumigatus after Selection with a Combination of the Triazole Fungicides Difenoconazole and Propiconazole

Antifungal Activity of Antifungal Drugs, as Well as Drug Combinations Against Exophiala dermatitidis

In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles

Interaction of Amiodarone with Azoles Against Aspergillus Planktonic Cells and Biofilms in vitro

Drug combinations against Mucor irregularis in vitro.

In vitro activity of terbinafine in combinations with other antifungi drugs against clinical pathogenic fungi of vulvovaginal candidiasis

Synergism of Caspofungin and Terbinafine Against Clinical and Environmental Isolates of Cryptococcus Neoformans

In vitro interactions of proton pump inhibitors and azoles against pathogenic fungi